Device Trial Radar · NCT06298981
Pulse Rate and Breathing Rate Accuracy
Last checked: Nov 20, 2026Latest source record: Mar 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
60
Planned (sponsor's estimate)
Start
Feb 12, 2024
Primary completion
Jun 30, 2024
Study completion Jun 30, 2024
Sponsor
- Lead sponsor
- Nuralogix CorporationNot on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 7, 2024
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 81 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to conduct a Breathing Rate and Pulse Rate accuracy validation comparing the NuraLogix AMC-SDK to the Reference devices, an FDA cleared End Tidal Carbon Dioxide monitor (GE Datex-Ohmeda) and a standard ECG (GE Datex-Ohmeda) derived heart rate reference. This will be done by manually scoring the collected waveform for data analysis.
Conditions
- Pulse Rate and Breathing Rate
Interventions
noninvasive and investigational NuraLogix AMC-SDKDevice
The NuraLogix AMC-SDK is a noninvasive device that allows for real-time, remote measuring using facial recordings.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Breathing rate accuracy validationTime frame: 1-2 hours
- Pulse rate accuracy validationTime frame: 1-2 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Element Materials Technology
Louisville, Colorado · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.